Inactive Instrument

Diffusion Pharma

Equities

DFFN

US2537484048

LifeSci Special Opportunities Master Fund Ltd Issues an Open Letter to Shareholders of Diffusion Pharmaceuticals Inc

November 18, 2022 at 05:00 pm IST

On November 18, 2022, LifeSci Special Opportunities Master Fund Ltd announced that it has sent an open letter to shareholders of Diffusion Pharmaceuticals Inc in response to CompanyÃ†s press release, highlighting CompanyÃ†s response against its discussions regarding potential strategic alternatives. In addition, LifeSci Special Opportunities Master Fund Ltd stated that it has nominated Jill Davidson, Tenzin Khangsar, Jeffrey Kimbell and urged the shareholders of the Company to vote for its board nominees at the annual meeting of shareholders scheduled to be held on December 30, 2022.

Latest news about Diffusion Pharma

Diffusion Pharmaceuticals Inc.(NasdaqCM:DFFN) dropped from NASDAQ Composite Index	17/23/17	CI
CervoMed Completes Merger with EIP Pharma	17/23/17	MT
EIP Pharma, Inc. completed the acquisition of Diffusion Pharmaceuticals Inc. in a reverse merger transaction.	16/23/16	CI
Diffusion Pharmaceuticals Shareholders Approve Merger With EIP Pharma; Shares Rise	16/23/16	MT
Diffusion Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/23/09	CI
Diffusion Pharmaceuticals Inc. Appoints Jill Davidson as A Director of the Company, Effective July 26, 2023	01/23/01	CI
Diffusion Pharmaceuticals Inc. Announces Resignation of William K. Hornung as CFO	20/23/20	CI
Diffusion Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
Top Premarket Gainers	17/23/17	MT
Diffusion Pharmaceuticals, EIP Pharma Agree to Merge to Create New Combined Entity	30/23/30	MT
EIP Pharma, Inc. entered into a definitive merger agreement to acquire Diffusion Pharmaceuticals Inc. for $22.2 million in a reverse merger transaction.	30/23/30	CI
Diffusion Pharmaceuticals Inc. Announces Resignation of Christopher D. Galloway as Chief Medical Officer, Effective March 1, 2023	17/23/17	CI
Diffusion Pharmaceuticals Enters Reaches Deal With LifeSci Special Opportunities Master Fund on Board Nominees	16/22/16	MT
Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities	16/22/16	CI
Diffusion Pharmaceuticals Inc Sends a Letter to Shareholders	05/22/05	CI
Diffusion Pharmaceuticals Inc Solicits Proxies from Shareholders	01/22/01	CI
Diffusion Pharmaceuticals Inc Solicits Proxies from Shareholders	29/22/29	CI
Diffusion Pharmaceuticals Inc Send a Letter to Shareholders	29/22/29	CI
LifeSci Special Opportunities Master Fund Ltd Issues an Open Letter to Shareholders of Diffusion Pharmaceuticals Inc	18/22/18	CI
LifeSci Special Nominates Candidates to the Board of Diffusion Pharmaceuticals	18/22/18	CI
LS Capital, Inc., on behalf of a client and unaffiliated investor in Diffusion Pharmaceuticals Inc. cancelled the acquisition of remaining shares of Diffusion Pharmaceuticals Inc..	17/22/17	CI
Diffusion Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/22/15	CI
Diffusion Pharmaceuticals Inc. Announces Resignation of Eric Francois from the Board of Directors and All Committees and Subcommittees	14/22/14	CI
Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives Including Opportunities to Better	25/22/25	CI
North American Morning Briefing : Investors Seek -2-	17/22/17	DJ

Chart Diffusion Pharma

Duration

Period

More charts

Company Profile

Diffusion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapies that may enhance the body's ability to deliver oxygen to the areas. Its advanced product candidate, Trans Sodium Crocetinate (TSC), is developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine's intractable and difficult-to-treat conditions, including hypoxic solid tumors, such as GBM. TSC is the therapeutic candidate specifically designed to enhance the oxygen diffusion process. By supporting normal, physiologic levels of oxygen diffusion at the uptake and delivery points of the circulatory system. Hypoxia is a complicating factor in many other intractable and difficult-to-treat conditions, including cardiovascular diseases, cerebrovascular diseases, respiratory diseases, skin and soft tissue diseases, and neurodegenerative diseases.

Sector

More about the company